Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Luveltamab Tazevibulin · STRO-002, SP-8193

Antibody-drug conjugate · Cytotoxic, directed at folate receptor alpha (FOLR1) · developed by Sutro Biopharma

Phase 2/3 Most advanced trial (none active)
STRO Developer
2 Registered trials

What is Luveltamab Tazevibulin?

Luveltamab tazevibulin is an antibody-drug conjugate in which an IgG1 antibody (SP8166) binds folate receptor alpha (FOLR1) on tumor cells. After internalization and cleavage of its linker, the released hemiasterlin warhead SC209 inhibits tubulin polymerization, causing mitotic arrest and cell death. It is being studied in ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
STRO-002, SP-8193, Luvelta
Drug type
Antibody-drug conjugate
Targets
folate receptor alpha (FOLR1)
Mechanism
Cytotoxic, directed at folate receptor alpha (FOLR1)
Pathways
tubulin polymerization inhibition, mitotic arrest, apoptosis
Therapy area
Oncology
Developer
Sutro Biopharma, Inc. (STRO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
XDE2GOF1JT

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05870748 Phase 2/3 Ovarian Cancer Terminated STRO
NCT06238687 Phase 1/2 Neoplasm Malignant Completed STRO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Epithelial Ovarian CancerFallopian Tube CancerNeoplasm MalignantOvarian CancerPlatinum-resistant Ovarian CancerPrimary Peritoneal Cancer

Other drugs acting on FOLR1

More from Sutro Biopharma

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the STRO page.

Follow STRO, the company behind Luveltamab Tazevibulin

See STRO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

STRO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.